EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access

HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405

Francesca Battaglin iD, Fang-Shu Ou iD, Xueping Qu, Howard S Hochster iD, Donna Niedzwiecki iD, Richard M Goldberg iD, Robert J Mayer, Karam Ashouri iD, Tyler J Zemla, Charles D Blanke, Alan P Venook iD, Omar Kabbarah und 2 weitere

Journal of Clinical Oncology · 01.06.2024 · 42 (16) · 1890-1902

DOI: 10.1200/jco.23.01507 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2024. Verfasst von Francesca Battaglin und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Bevacizumab, Cetuximab. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of HER2 amplification and gene expression using next-generation sequencing (NGS) and NanoString data. PATIENTS AND METHODS Primary tumor DNA from 559 patients was profiled for HER2 amplification by NGS (FoundationOne CDx). Tumor tissue from 925 patients was tested for NanoString gene expression using an 800-gene panel. OS and progression-free survival (PFS) were the time-to-event end points. RESULTS High HER2 expression (dichotomized at median) was associated with longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment. An OS benefit for cetuximab versus bevacizumab was observed in the high HER2 expression group ( P = .02), whereas a worse PFS for cetuximab was seen in the low-expression group ( P = .019). When modeled as a continuous variable, increased HER2 expression was associated with longer OS (hazard ratio [HR], 0.83 [95% CI, 0.75 to 0.93]; adjusted P = .0007) and PFS (HR, 0.82 [95% CI, 0.74 to 0.91]; adjusted P = .0002), reaching a plateau effect after the median. In patients with HER2 expression lower than median, treatment with cetuximab was associated with worse PFS (HR, 1.38 [95% CI, 1.12 to 1.71]; adjusted P = .0027) and OS (HR, 1.28 [95% CI, 1.02 to 1.59]; adjusted P = .03) compared with that with bevacizumab. A significant interaction between HER2 expression and the treatment arm was observed for OS ( P intx = .017), PFS ( P intx = .048), and objective response rate ( P intx = .001). CONCLUSION HER2 gene expression was prognostic and predictive in CALGB/SWOG 80405. HER2 tumor expression may inform treatment selection for patients with low HER2 favoring bevacizumab- versus cetuximab-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesBevacizumabCetuximabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedPrognosisAgedAdultProgression-Free SurvivalBiomarkers, TumorGene Expression Regulation, NeoplasticNeoplasm Metastasis

Substanzen

Erb-b2 Receptor Tyrosine KinasesBevacizumabCetuximabBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
  • Genentech, San Francisco, CA.
  • Yale Cancer Center, New Haven, CT.
  • Duke Cancer Institute, Duke University Medical Center, Durham, NC.
  • West Virginia University Cancer Institute, Morgantown, WV.

ORCID-Profile: Francesca Battaglin, Fang-Shu Ou, Howard S Hochster, Donna Niedzwiecki, Richard M Goldberg, Karam Ashouri, Alan P Venook, Heinz-Josef Lenz, Federico Innocenti

Förderung

  • NCI NIH HHS

Zitieren

APA

Battaglin, F., Ou, F. S., Qu, X., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Ashouri, K., Zemla, T. J., Blanke, C. D., Venook, A. P., Kabbarah, O., Lenz, H. J., & Innocenti, F. (2024). HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Journal of Clinical Oncology, 42(16), 1890-1902. https://doi.org/10.1200/jco.23.01507

Vancouver

Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, et al. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Journal of Clinical Oncology. 2024;42(16):1890-1902. doi:10.1200/jco.23.01507

BibTeX
@article{Battaglin2024,
  author = {Battaglin, Francesca and Ou, Fang-Shu and Qu, Xueping and Hochster, Howard S and Niedzwiecki, Donna and Goldberg, Richard M and Mayer, Robert J and Ashouri, Karam and Zemla, Tyler J and Blanke, Charles D and Venook, Alan P and Kabbarah, Omar and Lenz, Heinz-Josef and Innocenti, Federico},
  title = {HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {16},
  pages = {1890--1902},
  doi = {10.1200/jco.23.01507}
}
Kostenlos starten →